1. Home
  2. BTBT vs SKYE Comparison

BTBT vs SKYE Comparison

Compare BTBT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bit Digital Inc.

BTBT

Bit Digital Inc.

HOLD

Current Price

$2.17

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.11

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBT
SKYE
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
44.9M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BTBT
SKYE
Price
$2.17
$1.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.50
$14.75
AVG Volume (30 Days)
28.7M
567.0K
Earning Date
11-14-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
$105,703,143.00
N/A
Revenue This Year
$7.15
N/A
Revenue Next Year
$90.95
N/A
P/E Ratio
$3.54
N/A
Revenue Growth
7.86
N/A
52 Week Low
$1.69
$0.68
52 Week High
$4.55
$5.75

Technical Indicators

Market Signals
Indicator
BTBT
SKYE
Relative Strength Index (RSI) 48.51 54.19
Support Level $2.08 $0.68
Resistance Level $2.24 $0.95
Average True Range (ATR) 0.13 0.11
MACD 0.04 0.04
Stochastic Oscillator 67.35 83.92

Price Performance

Historical Comparison
BTBT
SKYE

About BTBT Bit Digital Inc.

Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: